Issue 4 - Jan 27, 2017
  • How a “cool” trial in rare cancers was born

    About a year ago, Sandip Patel, a young doctor who had just joined the faculty at University of California San Diego Moores Cancer Center, stopped by to see his mentor, Razelle Kurzrock, chair of the SWOG Early Therapeutics and Rare Cancers Committee.

  • MD Anderson posts $169 million loss for first four months of fiscal 2017

    MD Anderson Cancer Center lost $58 million during the month of December 2016.

    This latest operating loss brings total losses $169.4 million for the first four months of fiscal 2017, which began on Sept. 1, 2016.

  • In Brief

    • Miami Cancer Institute Opens, joins MSKCC Alliance
    • LUNGevity, CancerCare launch helpline
    • White paper shows challenges, progress in immunotherapy
    • Study finds undisclosed conflicts in Twitter posts by oncologists
  • Drugs & Targets

    • FDA approves first drug for marginal zone lymphoma
    • Merck, Domain Therapeutics collaborate in immune-oncology
Issue 3 - Jan 20, 2017
  • “Will I still have coverage?” patients ask oncologists as Republicans move to gut Affordable Care Act

    As Congress lays down the groundwork for dismantling the Affordable Care Act, doctors across America are hearing cancer patients speak of their fear of losing access to care if the law known as “Obamacare” is jettisoned without replacement.

  • FDA forms Oncology Center of Excellence, names Richard Pazdur director

    On his last full day as FDA commissioner, Robert Califf announced the formation of the Oncology Center of Excellence and named Richard Pazdur its director.

    The process of forming the center began in June, and Pazdur has been the acting director. Reorganization of the FDA oncology portfolio is an element of the Obama White House Moonshot Initiative.

  • Guest Editorial

    NCI formulary, moonshot and public-private partnerships

    Announcing the NCI Formulary, the Jan. 13 issue of The Cancer Letter includes comments suggesting the road to new therapies will now get “easier” and other comments indicated that industry and/or NCI collaborators will “not provide support other than drug access”.

  • In Brief

    • Richard Goldberg new director of West Virginia University Cancer Institute
    • Justin Klamerus named president of Karmanos Cancer Hospital
    • Werner-Wasik new executive vice chair, radiation oncology integration at Jefferson
    • Northwell Health partners with Indivumed to create cancer research biobank
    • Tempus and University Hospitals/Seidman announce effort to customize treatment
    • Reporting of lung cancer surgery outcomes provides info about quality of care
  • Drugs & Targets

    • Medicinal product designation for TB-403 for medulloblastoma
  • Funding Opportunities

    LUNGevity issues RFA for career development award

    LUNGevity announced a request for applications for translational research for career development awards that will be granted in 2017.

Issue 2 - Jan 13, 2017
  • NCI develops a “formulary” to make it easier for cancer centers to test drug combinations

    With a simplified tech transfer agreement, six industry partners and 15 compounds (but no dedicated research funds), NCI challenges investigators to think creatively.

  • Conversation with The Cancer Letter

    Simon: The moonshot will continue, but the electronic health record industry must step up

    The National Cancer Moonshot Initiative was created by a memorandum issued by President Barack Obama.

    The wide-ranging public health initiative will cease to exist on Jan. 20—eight days short of a year after it was created—when the keys to the White House are handed over to Donald Trump.

  • In Brief

    • Sakaguchi, Ramsdell, Rudensky win Crafoord Prize for discoveries in immune regulation
    • Gustavo Leone named director of  MUSC Hollings Cancer Center
    • Levine Cancer Institute is first to earn top designation for patient-centered care
    • Martin Edelman joins Fox Chase as hematology/oncology chair
    • Diane Simeone to lead pancreatic cancer center at NYU Langone
    • Mario Contreraz named administrator of IU cancer center clinical trials office
    • Columbia, NewYork-Presbyterian and Life Raft form GIST research partnership
    • NCCN publishes patient education resources for gliomas
    • NIHCM Foundation awards $345K in investigator-initiated research grants
    • LUNGevity Foundation introduces mobile app to help patients manage lung cancer
    • NPR station broadcasts anniversary program on moonshot
    • Goldberg novel is finalist in Jewish Book award
  • Drugs & Targets

    • Merck joins ORIEN
    • Scripps to collaborate with Pfizer to advance DNA-encoded library technology
    • AbbVie announces four new global research collaborations
    • Lilly and Merck expand immuno-oncology collaboration
    • Amgen and Immatics collaborate to develop cancer immunotherapies
    • Philips and Illumina to co-develop integrated genomics solutions for oncology
    • Tecentriq receives priority review for treatment of urothelial carcinoma
    • EMD Serono and MD Anderson enter three-year collaboration
    • MD Anderson and Deerfield Management create company to inhibit autophagy
    • Cologuard earns positive review from Blue Cross Blue Shield Association
    • FDA accepts BLA for Mylan and Biocon’s biosimilar Trastuzumab
    • FDA releases guidance on nonproprietary naming of biologics